File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Methotrexate, bleomycin, and etoposide in the treatment of gestational trophoblastic neoplasia

TitleMethotrexate, bleomycin, and etoposide in the treatment of gestational trophoblastic neoplasia
Authors
Issue Date2006
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.greenjournal.org
Citation
Obstetrics And Gynecology, 2006, v. 107 n. 5, p. 1012-1017 How to Cite?
AbstractOBJECTIVE: The combination of methotrexate (1 g/m 2 day 1), bleomycin (10 mg day 3), and etoposide (100 mg/m 2 days 1-5) (MBE) has been used for disease relapse or as a second-line chemotherapy in the treatment of gestational trophoblastic neoplasia (GTN) resistant to multiple-agent chemotherapy. With the identification of ultra-high-risk GTN, MBE has also been used as first-line chemotherapy. The current study is to review the use of MBE in the treatment of GTN. METHODS: Patients who received MBE for GTN between 1985 and 2003 in Queen Mary Hospital were included in this study. Records were reviewed and data were analyzed. Outcomes including response rate, treatment complications, and survival were assessed. RESULTS: Methotrexate, bleomycin, and etoposide therapy was given as first line to 4 patients with ultra-high-risk GTN. Three responded to the treatment and remained disease free. Methotrexate, bleomycin, and etoposide were given as a second-line therapy to 8 patients who had drug resistance to the initial therapy. Seven responded, and 6 remained disease free at 5 years. Methotrexate, bleomycin, and etoposide were given as a second-line therapy to 8 patients who relapsed 2-18 months after their initial therapy. Seven patients responded, and 4 remained disease-free at 5 years, 2 defaulted, and one died of carcinoma of the colon. Of the 20 patients who received MBE, 12 developed grade 3/4 neutropenia, and 4 developed grade 3/4 thrombocytopenia. The overall response rate for MBE was 85%. CONCLUSION: Methotrexate, bleomycin, and etoposide should be considered as a second-line therapy in patients who have drug-resistant or recurrent GTN. © 2006 by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/87088
ISSN
2015 Impact Factor: 5.656
2015 SCImago Journal Rankings: 2.899
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorTam, KFen_HK
dc.contributor.authorLam, KWen_HK
dc.contributor.authorChan, KKLen_HK
dc.date.accessioned2010-09-06T09:25:10Z-
dc.date.available2010-09-06T09:25:10Z-
dc.date.issued2006en_HK
dc.identifier.citationObstetrics And Gynecology, 2006, v. 107 n. 5, p. 1012-1017en_HK
dc.identifier.issn0029-7844en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87088-
dc.description.abstractOBJECTIVE: The combination of methotrexate (1 g/m 2 day 1), bleomycin (10 mg day 3), and etoposide (100 mg/m 2 days 1-5) (MBE) has been used for disease relapse or as a second-line chemotherapy in the treatment of gestational trophoblastic neoplasia (GTN) resistant to multiple-agent chemotherapy. With the identification of ultra-high-risk GTN, MBE has also been used as first-line chemotherapy. The current study is to review the use of MBE in the treatment of GTN. METHODS: Patients who received MBE for GTN between 1985 and 2003 in Queen Mary Hospital were included in this study. Records were reviewed and data were analyzed. Outcomes including response rate, treatment complications, and survival were assessed. RESULTS: Methotrexate, bleomycin, and etoposide therapy was given as first line to 4 patients with ultra-high-risk GTN. Three responded to the treatment and remained disease free. Methotrexate, bleomycin, and etoposide were given as a second-line therapy to 8 patients who had drug resistance to the initial therapy. Seven responded, and 6 remained disease free at 5 years. Methotrexate, bleomycin, and etoposide were given as a second-line therapy to 8 patients who relapsed 2-18 months after their initial therapy. Seven patients responded, and 4 remained disease-free at 5 years, 2 defaulted, and one died of carcinoma of the colon. Of the 20 patients who received MBE, 12 developed grade 3/4 neutropenia, and 4 developed grade 3/4 thrombocytopenia. The overall response rate for MBE was 85%. CONCLUSION: Methotrexate, bleomycin, and etoposide should be considered as a second-line therapy in patients who have drug-resistant or recurrent GTN. © 2006 by The American College of Obstetricians and Gynecologists. Published by Lippincott Williams & Wilkins.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.greenjournal.orgen_HK
dc.relation.ispartofObstetrics and Gynecologyen_HK
dc.rightsObstetrics and Gynecology. Copyright © Lippincott Williams & Wilkins.en_HK
dc.titleMethotrexate, bleomycin, and etoposide in the treatment of gestational trophoblastic neoplasiaen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0029-7844&volume=107&issue=5&spage=1012&epage=1017&date=2006&atitle=Methotrexate,+bleomycin,+and+etoposide+in+the+treatment+of+gestational+trophoblastic+neoplasia+en_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.emailChan, KKL:kklchan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.identifier.authorityChan, KKL=rp00499en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.AOG.0000207577.67765.8een_HK
dc.identifier.pmid16648404-
dc.identifier.scopuseid_2-s2.0-33646816029en_HK
dc.identifier.hkuros119718en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33646816029&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume107en_HK
dc.identifier.issue5en_HK
dc.identifier.spage1012en_HK
dc.identifier.epage1017en_HK
dc.identifier.isiWOS:000241296500007-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridTam, KF=7201692816en_HK
dc.identifier.scopusauthoridLam, KW=13407245500en_HK
dc.identifier.scopusauthoridChan, KKL=8655666700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats